Summary
Plasma and whole blood concentrations of proguanil, its active metabolite cycloguanil, and the inactive metabolite 4-chlorophenyl-biguanide, were measured by HPLC in 10 healthy Karen women in the last trimester of pregnancy, following a 200 mg single oral dose of proguanil. Four of these women were restudied 2 months after delivery.
The pharmacokinetic properties of proguanil were similar during and after pregnancy. Median peak plasma concentrations of proguanil during pregnancy and following delivery were 212 and 215 ng·ml−1, and occurred at 4.5 and 5 h, respectively. Mean plasma AUC values for proguanil during and following pregnancy were 94 and 98 ng·h·ml−1·kg−1, respectively. Corresponding whole blood AUC values were 361 and 396 ng·h·ml−1·kg−1. The mean elimination half lives and mean residence times of proguanil in plasma and whole blood were 12.3 and 19.6 h and 13.8 and 20.7 h respectively during pregnancy. Following pregnancy these values were 17.1 and 19.7 h for plasma and 19.7 h and 20.2 h for whole blood respectively.
Mean peak plasma and whole blood concentrations of cycloguanil following pregnancy were 25 and 22 ng·ml−1 respectively. During pregnancy peak cycloguanil concentrations in both plasma and whole blood were markedly lower, 13 and 12 ng ml−1, respectively. Two pregnant women (neither of whom were restudied) were probably poor metabolisers of proguanil. The mean ratio of proguanil to cycloguanil plasma AUC was 16.7 in the third trimester of pregnancy and 7.8 following pregnancy, compared with less than 5 in previously reported studies. The concentrations of 4-chlorophenylbiguanide in both plasma and whole blood in pregnant subjects were also lower than those after pregnancy.
These data show that blood concentrations of the active antimalarial metabolite cycloguanil are reduced in late pregnancy and that the currently recommended dose of proguanil could be inadequate for antimalarial prophylaxis in pregnant women.
Similar content being viewed by others
References
Bygbjerg I, Ravn P, Ronn H, Flachs H, Hvidberj EF (1987) Human pharmacokinetics of proguanil and its metabolites. Trop Med Parasit 38: 77–80
Chiluba EM, Fletcher KA, Price AH (1987) The pharmacokinetics of proguanil in human subjects following a single oral dose. Afr J Med Sci 16: 43–46
Dixon WJ editor (1985) BMDP statistical software manual. University of California Press, California
Edstein MD (1986) Simultaneous measurement of proguanil and cycloguanil in human plasma by high-performance liquid chromatography. J Chromatogr 380: 184–189
Edstein MD, Veenendaal JR, Scott HV, Rieckmann KH (1988) Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man. Chemotherapy 34: 385–392
Helsby NA, Ward SA, Howells RE, Breckenridge AM (1990a) Invitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxlyase (P450MP) enzyme. Brit J Clin Pharmacol 30: 287–291
Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM (1990b) The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Brit J Clin Pharmacol 30: 593–598
Jurima M, Inaba T, Kadar P, Kalow W (1985a) Genetic polymorphism of mephenytoin p (4) hydroxylation: difference between Orientals and Caucasians. Brit J Clin Pharmacol 19: 383–387
Jurima M, Inaba T, Kalow W (1985b) Mephenytoin hydroxylase activity in human liver: inhibition by steroids. Drug Metabol Disp 13: 746–749
Maegraith BG, Tottey MM, Adams ARD, Andrews WHH, King JD (1946) The absorption and excretion of Paludrine in human subjects. Ann Trop Med Parasit 40: 493–506
Nosten F, ter Kuile F, Maelankirri L, Decludt B, White NJ (1991) Malaria in pregnancy in an area of unstable transmission. Trans R Soc Trop Med Hyg, 85: 424–429
Taylor RB, Moody RR, Ochekpe NA (1987) Determination of proguanil and its metabolites cycloguanil and 4-chlorophenylbiguanide in plasma, whole blood and urine by HPLC. J Chromatogr 416: 394–399
Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM (1991) The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism — a panel study. Brit J Clin Pharmacol 31: 689–692
Watkins WM, Chulay JD, Sixsmith DG, Spencer HC, Howells RE (1987) A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. J Pharm Pharmacol 39: 261–265
Watkins WM, Mberu EK, Neville CG, Ward SA, Breckenridge AM (1990) Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan subjects. Trans R Soc Trop Med Hyg 84: 492–495
Wattanagoon Y, Taylor RB, Moody RR, Ochekpe NA, Looareesuwan S, White NJ (1987) Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. Br J clin Pharmac 24: 775–780
White NJ (1985) Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 10: 187–215
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wangboonskul, J., White, N.J., Nosten, F. et al. Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. Eur J Clin Pharmacol 44, 247–251 (1993). https://doi.org/10.1007/BF00271366
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00271366